WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
Open Access
- 1 January 2018
- journal article
- review article
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 10 (1), e2018004
- https://doi.org/10.4084/mjhid.2018.004
Abstract
Waldenstrom Macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical features. Diagnostic and prognostic charactrization in WM significantly changed with the discovery of two molecular markers: MYD88 and CXCR4. Mutational status of these latter influences both clinical presentation and prognosis and demonstrated therapeutic implications. Treatment choice in Waldemstrom disease is strictly guided by patients age and characteristics, specific goals of therapy, necessity for rapid disease control, risk of treatment-related neuropathy, disease characteristics, risk of immunosuppression or secondary malignancies and potential for future autologous stem cell transplantation. Therapeutic landscape has expanded during the last years and the approval of ibrutinib, the first drug approved for Waldenstrom Macroglobulinemia, represents an important step forward for a better management of the disease.This publication has 119 references indexed in Scilit:
- Familial Aggregation of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia with Solid Tumors and Myeloid MalignanciesActa Haematologica, 2012
- Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's MacroglobulinemiaClinical Cancer Research, 2010
- Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180Journal of Clinical Oncology, 2009
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's MacroglobulinemiaCancer Research, 2009
- Thalidomide and rituximab in Waldenstrom macroglobulinemiaBlood, 2008
- Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in SwedenBlood, 2008
- SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemiaBlood, 2008
- The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaBlood, 2007
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003